Cytokinetic-driven myeloprotection after cytotoxic chemotherapy: from an old idea to a new clinical approach.
Chemotherapy
Myeloprotection
Myelotoxicity
Stimulating factors
Trilaciclib
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
19
11
2021
accepted:
21
04
2022
pubmed:
29
4
2022
medline:
20
8
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
Chemotherapy is the backbone of the treatment of several solid tumours and lymphomas. Myelotoxicity is often a dose-limiting toxicity and myeloprotection has always been investigated. In fact, over the years, several approaches have been studied in order to reduce the incidence of haematological toxicities and allow patients to receive effective, full-dose, chemotherapy. After the use of stimulating factors, such as granulocyte colony-stimulating factors and erythropoiesis-stimulating agents, in the very last years, a new approach has emerged. Trilaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, has been studied and it has been demonstrated in several clinical trials to reduce the incidence of myelotoxicity in small-cell lung cancer patients treated with chemotherapy or chemo-immunotherapy. Its potential role has not been fully studied yet, but it represents a highly effective tool to reduce myelotoxicity, widen the applicability of full-dose chemotherapy, even in frailer patients, and finally to increase the efficacy of chemotherapy in those tumours where relative dose intensity is a standard to achieve to get the best clinical results.
Identifiants
pubmed: 35484313
doi: 10.1007/s00520-022-07084-5
pii: 10.1007/s00520-022-07084-5
doi:
Substances chimiques
Antineoplastic Agents
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7057-7060Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J (2021) Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. https://doi.org/10.1002/onco.13822
Shayne M, Harvey RD, Lyman GH (2021) Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity. Expert Rev Anticancer Ther. https://doi.org/10.1080/14737140.2021.1941891
Mølby AW, Laursen BE, Falkmer U, McCulloch T, Jensen NA, Poulsen LØ Up front chemotherapy dosing and relative dose intensity in extensive stage small cell lung cancer. Ann Oncol 28:ii17–ii18. https://doi.org/10.1093/annonc/mdx088.004
Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist. 5:224–237
doi: 10.1634/theoncologist.5-3-224
Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A. 86(23):9499–9503
doi: 10.1073/pnas.86.23.9499
Sung L, Dror Y (2007) Clinical applications of granulocyte-colony stimulating factor. Front Biosci. 12:1988–2002. https://doi.org/10.2741/2204
doi: 10.2741/2204
pubmed: 17127437
Jelkmann W (2013) Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 40(5):302–309. https://doi.org/10.1159/000356193
doi: 10.1159/000356193
pubmed: 24273483
pmcid: 3822280
Danova M, Aglietta M (1997) Cytokine receptors, growth factors and cell cycle in human bone marrow and peripheral blood hematopoietic progenitors. Haematologica. 82(5):622–629
pubmed: 9407736
Tjan-Heijnen VC, Biesma B, Festen J, Splinter TA, Cox A, Wagener DJ, Postmus PE (1998) Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma. J Clin Oncol 16(8):2708-14. 10.1200/JCO.1998.16.8.2708. Erratum in: J Clin Oncol 1999;17(3):1091
Riccardi A, Danova M, Paccagnella A, Giordano M, Favaretto A, Panozzo M, Ghiotto C, Comis S, Fiorentino M, Chieco-Bianchi L et al (1993) Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor. Ann Hematol. 66(4):185–193. https://doi.org/10.1007/BF01703234
doi: 10.1007/BF01703234
pubmed: 8387346
Danova M, Rosti V, Mazzini G, De Renzis MR, Locatelli F, Cazzola M, Riccardi A, Ascari E (1995) Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. Int J Cancer. 63(5):646–651. https://doi.org/10.1002/ijc.2910630508
doi: 10.1002/ijc.2910630508
pubmed: 7591280
Janik JE, Miller LL, Korn EL, Stevens D, Curti BD, Smith JW 2nd, Sznol M, Conlon KC, Sharfman W, Urba WJ, Gause BL, Longo DL (2001) A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood. 97(7):1942–1946. https://doi.org/10.1182/blood.v97.7.1942
doi: 10.1182/blood.v97.7.1942
pubmed: 11264156
Bisi JE, Sorrentino JA, Roberts PJ et al (2016) Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression. Mol Cancer Ther 15(5):783–793.2
doi: 10.1158/1535-7163.MCT-15-0775
He S, Roberts PJ, Sorrentino JA et al (2017) Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med 9:eaal3986
doi: 10.1126/scitranslmed.aal3986
Weiss JM, Csoszi T, Maglakelidze M et al (2019) Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 30(10):1613–1621. https://doi.org/10.1093/annonc/mdz278
doi: 10.1093/annonc/mdz278
pubmed: 31504118
pmcid: 6857609
Hart LL, Ferrarotto R, Andric ZG, Thaddeus Beck J, Subramanian J, Radosavljevic DZ, Zaric B, Hanna WT, Aljumaily R, Owonikoko TK, Verhoeven D, Xiao J, Morris SR, Antal JM, Hussein MA (2021) Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther 38(1):350–365 Published online 2020 Oct 29. 10.1007/s12325-020-01538-0
doi: 10.1007/s12325-020-01538-0
Hussein M, Maglakelidze M, Richards DA, Sabatini M, Gersten TA, Lerro K, Sinielnikov I, Spira A, Pritchett Y, Antal JM, Malik R, Beck JT (2021) Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res. 13:6207–6218. https://doi.org/10.2147/CMAR.S313045
doi: 10.2147/CMAR.S313045
pubmed: 34408488
pmcid: 8363477
Ferrarotto R, Anderson I, Medgyasszay B, García-Campelo MR, Edenfield W, Feinstein TM, Johnson JM, Kalmadi S, Lammers PE, Sanchez-Hernandez A, Pritchett Y, Morris SR, Malik RK, Csőszi T (2021) Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: pooled analysis of three randomized phase 2 trials. Cancer Med. 10(17):5748–5756. https://doi.org/10.1002/cam4.4089
doi: 10.1002/cam4.4089
pubmed: 34405547
pmcid: 8419768
Daniel D, Kuchava V, Bondarenko I, Ivashchuk O, Reddy S, Jaal J, Kudaba I, Hart L, Matitashvili A, Pritchett Y, Morris SR, Sorrentino JA, Antal JM, Goldschmidt J (2021) Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer 148(10):2557–2570 Published online 2021 Jan 12. 10.1002/ijc.33453
doi: 10.1002/ijc.33453
Watanabe H, Karayama M, Yasui H, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suda T (2021) Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide. Cancer Treat Res Commun 29. https://doi.org/10.1016/j.ctarc.2021.100493
Engert A (2005) Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol. 16(10):1584–1595. https://doi.org/10.1093/annonc/mdi307
doi: 10.1093/annonc/mdi307
pubmed: 15958437
Little NG, McBride A, Henry N, MacDonald K, Abraham I (2021) Comparative cost-efficiency analysis of trilaciclib, a novel CDK4/6 inhibitor, in the prophylaxis of chemotherapy-induced myelosuppression. Blood 138(Suppl 1):1907. https://doi.org/10.1182/blood-2021-146935
doi: 10.1182/blood-2021-146935
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F (2021) Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin Cancer Res. clincanres.0715.2021. https://doi.org/10.1158/1078-0432.CCR-21-0715